VENUS REMEDIES 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES 2017-18 Annual Report Analysis
Fri, 21 Dec

VENUS REMEDIES has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

VENUS REMEDIES Income Statement Analysis

  • Operating income during the year fell 6.9% on a year-on-year (YoY) basis.
  • The company's operating profit decreased by 22.2% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 10.6% in FY18 as against 12.7% in FY17.
  • Depreciation charges decreased by 16.0% and finance costs increased by 3.1% YoY, respectively.
  • Other income declined by 0.9% YoY.
  • Net profit for the year grew by 79.7% YoY.
  • Net profit margins during the year declined from 4.2% in FY17 to 8.2% in FY18.

VENUS REMEDIES Income Statement 2017-18

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Net Sales Rs m 4,000 3,724 -6.9%
Other income Rs m 23 23 -0.9%
Total Revenues Rs m 4,023 3,747 -6.9%
Gross profit Rs m 507 395 -22.2%
Depreciation Rs m 403 338 -16.0%
Interest Rs m 344 354 3.1%
Profit before tax Rs m -216 -275 27.2%
Tax Rs m -46 32 -169.3%
Profit after tax Rs m -171 -307 79.7%
Gross profit margin % 12.7 10.6
Effective tax rate % 21.1 -11.5
Net profit margin % -4.2 -8.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



VENUS REMEDIES Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 2 billion as compared to Rs 2 billion in FY17, thereby witnessing an increase of 17.1%.
  • Long-term debt down at Rs 1 billion as compared to Rs 2 billion during FY17, a fall of 15.1%.
  • Current assets rose 2% and stood at Rs 3 billion, while fixed assets fell 4% and stood at Rs 5 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 8 billion as against Rs 8 billion during FY17, thereby witnessing a fall of 2%.

VENUS REMEDIES Balance Sheet as on March 2018

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Networth Rs m 3,887 3,619 -6.9
 
Current Liabilities Rs m 1,968 2,305 17.1
Long-term Debt Rs m 1,618 1,374 -15.1
Total Liabilities Rs m 7,650 7,509 -1.8
 
Current assets Rs m 2,594 2,638 1.7
Fixed Assets Rs m 5,056 4,871 -3.7
Total Assets Rs m 7,650 7,509 -1.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



VENUS REMEDIES Cash Flow Statement Analysis

  • VENUS REMEDIES's cash flow from operating activities (CFO) during FY18 stood at Rs 514 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -123 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs -387 million, an improvement of 12% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs 4 million from the Rs -35 million net cash flows seen during FY17.

VENUS REMEDIES Cash Flow Statement 2017-18

Particulars No. of months 12 12 % Change
Year Ending Mar-17 Mar-18
Cash Flow from Operating Activities Rs m 589 514 -12.7%
Cash Flow from Investing Activities Rs m -183 -123 -
Cash Flow from Financing Activities Rs m -441 -387 -
Net Cash Flow Rs m -35 4 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for VENUS REMEDIES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs -24.9, an decline from the EPS of Rs -13.8 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 45.4, stands at -3.8 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 0.3 times, while the price to sales ratio stands at 0.3 times.
  • The company's price to cash flow (P/CF) ratio stood at 16.5 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Sales per share (Unadj.) Rs 324.2 301.8
TTM Earnings per share Rs -13.8 -24.9
Diluted earnings per share Rs -14.9 -26.8
Price to Cash Flow x 2.4 16.5
TTM P/E ratio x -4.1 -3.8
Price / Book Value ratio x 0.3 0.3
Market Cap Rs m 560 519
Dividends per share (Unadj.) Rs 0.0 0.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for VENUS REMEDIES

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.1x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 0.2x during FY18, from 0.4x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at -8.5% during FY18, from -4.4% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 1.6% during FY18, from 2.3% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 0.6% during FY18, from 2.3% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Current ratio x 1.3 1.1
Debtors’ Days Days 43 46
Interest coverage x 0.4 0.2
Debt to equity ratio x 0.4 0.4
Return on assets % 2.3 0.6
Return on equity % -4.4 -8.5
Return on capital employed % 2.3 1.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how VENUS REMEDIES has performed over the last 5 years, please visit here.

VENUS REMEDIES Share Price Performance

Over the last one year, VENUS REMEDIES share price has moved up from Rs 103.6 to Rs 45.4, registering a loss of Rs 58.2 or around 56.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,922.3 (up 0.1%). Over the last one year it has moved down from 14,407.3 to 13,922.3, a loss of 485 points (down 3.4%).

Overall, the S&P BSE SENSEX is up 7.7% over the year.

(To know more, check out historical annual results for VENUS REMEDIES and quarterly results for VENUS REMEDIES)

Equitymaster requests your view! Post a comment on "VENUS REMEDIES 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - CADILA HEALTHCARE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS